Ofatumumab approved dose
BiologicalApproved dosage
NCT Number: NCT06869785
This study will evaluate the pharmacokinetics, pharmacodynamics, safety and tolerability of a new dosage of ofatumumab compared to the approved dosage of ofatumumab followed by extended treatment in participants with relapsing multiple sclerosis.
This study is active but is not currently recruiting participants.
Notify Me18 year–100 year
All sexes
Interventional
Phase 3
Puerto Rico Multiple Sclerosis Ctr, Caguas, Puerto Rico
This is a Phase 3, open label, parallel-group, multicenter study in participants with relapsing multiple sclerosis
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Other protocol-defined inclusion/exclusion criteria may apply
Approved dosage
New dosage
Time frame: Up to 12 weeks
Time frame: Up to 12 weeks
Time frame: Up to 12 weeks
Time frame: Up to 52 weeks
Time frame: Up to 52 weeks
Time frame: Up to 52 weeks
Novartis Pharmaceuticals
Industry
An Open-label, Randomized, Parallel Group, Non-inferiority Study to Investigate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab, Followed by Extended Treatment in Participants With Relapsing Multiple Sclerosis
Acronym: FILIOS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04130997
Relapsing Multiple Sclerosis (RMS)
Pasadena, California, United States
View Trial DetailsNCT06486779
Relapsing Multiple Sclerosis (RMS)
Athens, Attica, Greece
View Trial DetailsNCT04667949
Relapsing Multiple Sclerosis (RMS)
Beijing, Beijing Municipality, China
View Trial DetailsNCT03745144
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Bochum, Germany
View Trial Details